⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Tofacitinib and JAK Inhibitors
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-10-05 — Senotherapeutic potential against xeroderma pigmentosum.: cross-connection with senomorphics: JAK inhibition emerges as the senomorphic lever in an XP photoaging model, linking the JAK-inhibitor class to SASP suppression in UV-stressed melanocytes. (novelty: 3)
- 2026-07-12 — Targeting the JAK-STAT signaling pathway ameliorates chemotherapy-induced skin aging.: cross-connection with ruxolitinib: Adds chemo-induced skin aging to the shared JAK-inhibitor senomorphic rationale already captured for tofacitinib and related JAKi. (novelty: 3)
- 2026-09-29 — Long-Term Human Skin Platform for Modeling Chronic Inflammation, Environmental Stress, and Therapeutic Intervention.: Long-term (up to 4 weeks) human skin explant platform study: tofacitinib broadly suppressed IL-17/IL-22-driven chronic inflammatory transcriptional programs, histopathology, and persistent secretion of IL-8, MCP-1, S100A8/A9, and MMP-1 — first ex vivo human-tissue readout for a JAK inhibitor in a chronic-inflammation aging context, no in vivo outcome data. [mechanism-plausible] (novelty: 3)
Open questions
Related
Contributing findings
Long-Term Human Skin Platform for Modeling Chronic Inflammation, Environmental Stress, and Therapeutic Intervention.
29-sep-2026
novelty 3
per-area 3
strengthens